Literature DB >> 25883229

The traumatic side of fibrinolysis.

Robert L Medcalf1.   

Abstract

In this issue of Blood, Hijazi et al challenge the view that consumptive coagulopathy that accompanies traumatic brain injury (TBI) results in a sequence of events that lead to intracranial hemorrhage (ICH).

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25883229     DOI： 10.1182/blood-2015-02-629808

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


  10 in total

1.  Tranexamic acid is an active site inhibitor of urokinase plasminogen activator.

Authors:  Guojie Wu; Blake A Mazzitelli; Adam J Quek; Matthew J Veldman; Paul J Conroy; Tom T Caradoc-Davies; Lisa M Ooms; Kellie L Tuck; Jonathan G Schoenecker; James C Whisstock; Ruby H P Law
Journal:  Blood Adv       Date:  2019-03-12

Review 2.  Advances in the understanding of trauma-induced coagulopathy.

Authors:  Ronald Chang; Jessica C Cardenas; Charles E Wade; John B Holcomb
Journal:  Blood       Date:  2016-07-05       Impact factor: 22.113

3.  Tranexamic acid to reduce head injury death in people with traumatic brain injury: the CRASH-3 international RCT.

Authors:  Ian Roberts; Haleema Shakur-Still; Amy Aeron-Thomas; Danielle Beaumont; Antonio Belli; Amy Brenner; Madeleine Cargill; Rizwana Chaudhri; Nicolas Douglas; Lauren Frimley; Catherine Gilliam; Amber Geer; Zahra Jamal; Rashid Jooma; Raoul Mansukhani; Alec Miners; Jason Pott; Danielle Prowse; Temitayo Shokunbi; Jack Williams
Journal:  Health Technol Assess       Date:  2021-04       Impact factor: 4.014

4.  Tranexamic acid in bleeding trauma patients: an exploration of benefits and harms.

Authors:  Ian Roberts; Phil Edwards; David Prieto; Miland Joshi; Abda Mahmood; Katharine Ker; Haleema Shakur
Journal:  Trials       Date:  2017-01-31       Impact factor: 2.279

5.  Disseminated intravascular coagulation with increased fibrinolysis during the early phase of isolated traumatic brain injury.

Authors:  Takeshi Wada; Satoshi Gando; Kunihiko Maekaw; Kenichi Katabami; Hisako Sageshima; Mineji Hayakawa; Atsushi Sawamura
Journal:  Crit Care       Date:  2017-08-22       Impact factor: 9.097

6.  Tranexamic acid is associated with selective increase in inflammatory markers following total knee arthroplasty (TKA): a pilot study.

Authors:  Andrea L Grant; Hayley L Letson; Jodie L Morris; Peter McEwen; Kaushik Hazratwala; Matthew Wilkinson; Geoffrey P Dobson
Journal:  J Orthop Surg Res       Date:  2018-06-18       Impact factor: 2.359

7.  What concentration of tranexamic acid is needed to inhibit fibrinolysis? A systematic review of pharmacodynamics studies.

Authors:  Roberto Picetti; Haleema Shakur-Still; Robert L Medcalf; Joseph F Standing; Ian Roberts
Journal:  Blood Coagul Fibrinolysis       Date:  2019-01       Impact factor: 1.276

8.  Fibrinolytic system activation immediately following trauma was quickly and intensely suppressed in a rat model of severe blunt trauma.

Authors:  Mineji Hayakawa; Takumi Tsuchida; Yoshinori Honma; Asumi Mizugaki; Takayoshi Ooyasu; Tomonao Yoshida; Tomoyo Saito; Kenichi Katabami; Takeshi Wada; Kunihiko Maekawa
Journal:  Sci Rep       Date:  2021-10-13       Impact factor: 4.379

9.  Increased urokinase and consumption of α2 -antiplasmin as an explanation for the loss of benefit of tranexamic acid after treatment delay.

Authors:  C Longstaff; M Locke
Journal:  J Thromb Haemost       Date:  2018-12-13       Impact factor: 5.824

10.  Effects of tranexamic acid on death, disability, vascular occlusive events and other morbidities in patients with acute traumatic brain injury (CRASH-3): a randomised, placebo-controlled trial.

Authors: 
Journal:  Lancet       Date:  2019-10-14       Impact factor: 202.731
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.